“Absolutely novel and exciting”—that is how Frans Moll (University Medical Center Utrecht, Utrecht, The Netherlands) has described the aXess haemodialysis vascular graft as he reviewed the findings from a first-in-human trial at the 2023 Charing Cross Symposium (25–27 April, London, UK).
Unassisted primary patency was found to be 80% at six months, while assisted was 89%. Highlighting the low rate of reintervention, Moll looks forward to the longer-term results from the study and argues that the graft promises “a bright future for our dialysis patients”.
